- Home
- CRT vs KPTI Comparison
CRT vs KPTI Comparison
Compare CRT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | KPTI |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 47.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CRT | KPTI |
|---|---|---|
| Price | $10.45 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 16.5K | ★ 2.3M |
| Earning Date | 04-14-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $7.07 | $1.79 |
| 52 Week High | $11.10 | $10.99 |
Technical Indicators
Market Signals| Indicator | CRT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 21.71 |
| Support Level | $10.15 | N/A |
| Resistance Level | $11.02 | $2.18 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 90.35 | 32.81 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).